{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:10:19Z","timestamp":1790485819039,"version":"4.1.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chronic myelomonocytic leukemia (CMML) is a rare clonal haematological malignancy bearing characteristics of both myelodysplastic syndromes and myeloproliferative neoplasms. It primarily affects older people (median age at diagnosis ~72 years). There are many challenges encountered in its treatment. One striking issue is the lack of strong clinical evidence from large randomized clinical trials for treating this disease. Another issue is that patients with CMML have highly variable outcomes with current treatments. Additional challenges include a wider application of current knowledge, an improved understanding of pathogenesis, development of new therapies, and management of refractory cases\/disease progression. It is clear that there is still progress to be made. Here, we review the available first-line treatment options for advanced CMML. Emphasis has been placed on choosing between hypomethylating agents and cytotoxic treatments, on the basis on disease-specific and patient-specific characteristics. A proper selection between these two treatments could lead to a better quality of care for patients with CMML.<\/jats:p>","DOI":"10.3389\/fonc.2021.801524","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T05:25:50Z","timestamp":1639373150000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?"],"prefix":"10.3389","volume":"11","author":[{"given":"Konstantinos","family":"Liapis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kotsianidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am J Hematol"},{"key":"B2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/S2352-3026(19)30069-9","article-title":"Forging a Path for Chronic Myelomonocytic Leukaemia","volume":"6","year":"2019","journal-title":"Lancet Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.5045\/br.2021.2020321","article-title":"Diagnosis and Treatment of Chronic Myelomonocytic Leukemia","volume":"56","author":"Kwon","year":"2021","journal-title":"Blood Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and Validation of a Prognostic Scoring System for Patients With Chronic Myelomonocytic Leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.88","article-title":"Mayo Prognostic Model for WHO-Defined Chronic Myelomonocytic Leukemia: ASXL1 and Spliceosome Component Mutations and Outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1540783","article-title":"Chronic Myelomonocytic Leukemia Treated With 5-Azacytidine - Results From the Hellenic 5-Azacytidine Registry: Proposal of a New Risk Stratification System","volume":"60","author":"Diamantopoulos","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating Clinical Features and Genetic Lesions in the Risk Assessment of Patients With Chronic Myelomonocytic Leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations From an International Expert Panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of Azacitidine Compared With That of Conventional Care Regimens in the Treatment of Higher-Risk Myelodysplastic Syndromes: A Randomised, Open-Label, Phase III Study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664","article-title":"International Phase 3 Study of Azacitidine vs Conventional Care Regimens in Older Patients With Newly Diagnosed AML With >30% Blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"B16","volume-title":"Vidaza (Azacitidine) [Package Insert]","year":"2019"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25759","article-title":"Activity of Azacitidine in Chronic Myelomonocytic Leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive Factors of Response and Survival Among Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.730615","article-title":"Treatment of Chronic Myelomonocytic Leukemia With Azacitidine","volume":"54","author":"Wong","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.719617","article-title":"High Rate of Remissions in Chronic Myelomonocytic Leukemia Treated With 5-Azacytidine: Results of an Italian Retrospective Study","volume":"54","author":"Fianchi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.85","article-title":"A Multi-Centre Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukaemia","volume":"28","author":"Drummond","year":"2014","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1138295","article-title":"A Phase II Study of the Efficacy, Safety, and Determinants of Response to 5-Azacitidine (Vidaza\u00ae) in Patients With Chronic Myelomonocytic Leukemia","volume":"57","author":"Tantravahi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of Decitabine in the Treatment of Patients With Chronic Myelomonocytic Leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular Predictors of Response to Decitabine in Advanced Chronic Myelomonocytic Leukemia: A Phase 2 Trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017","article-title":"A Phase II, Multicentre Trial of Decitabine in Higher-Risk Chronic Myelomonocytic Leukemia","volume":"32","author":"Santini","year":"2018","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1105371","article-title":"Hypomethylating Agents Are Effective in Shrinking Splenomegaly in Patients With Chronic Myelomonocytic Leukemia","volume":"57","author":"Subari","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30374-4","article-title":"Outcomes of Patients With Chronic Myelomonocytic Leukaemia Treated With non-Curative Therapies: A Retrospective Cohort Study","volume":"8","author":"Pleyer","year":"2021","journal-title":"Lancet Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ajh.24735","article-title":"Natural History of Chronic Myelomonocytic Leukemia Treated With Hypomethylating Agents","volume":"92","author":"Alfonso","year":"2017","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10767","article-title":"Mutation Allele Burden Remains Unchanged in Chronic Myelomonocytic Leukaemia Responding to Hypomethylating Agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2019045","DOI":"10.4084\/MJHID.2019.045","article-title":"Azacytidine Failure Revisited: An Appraisal Based on Real-Life Data From the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)","volume":"11","author":"Kotsianidis","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.1.65","article-title":"Acute Myeloid Leukemia Arising From Chronic Myelomonocytic Leukemia During Hypomethylating Therapy","volume":"49","author":"Niscola","year":"2014","journal-title":"Blood Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.10.015","article-title":"Has Introduction of Azacytidine in Everyday Clinical Practice Improved Survival in Late-Stage Myelodysplastic Syndrome? A Single Center Experience","volume":"38","author":"Papoutselis","year":"2014","journal-title":"Leuk Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"key":"B34","article-title":"The American Society of Hematology\u201563rd Annual Meeting and Exposition. Molecular International Prognosis Scoring System for Myelodysplastic Syndromes","author":"Bernard","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07524.x","article-title":"The Role of Aggressive Chemotherapy in the Treatment of the Myelodysplastic Syndromes","volume":"63","author":"Tricot","year":"1986","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/2040620713519742","article-title":"Outcomes of Patients With Myelodysplatic Syndrome and Chronic Myelomonocytic Leukemia Post Clofarabine Failure","volume":"5","author":"Ghanem","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ejh.12549","article-title":"Chronic Myelomonocytic Leukemia With Nucleophosmin (NPM1) Mutation","volume":"96","author":"Peng","year":"2016","journal-title":"Eur J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24861","article-title":"Nucleophosmin 1 (NPM1) Mutations in Chronic Myelomonocytic Leukemia and Their Prognostic Relevance","volume":"92","author":"Vallapureddy","year":"2017","journal-title":"Am J Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic Stem Cell Transplantation of Adult Chronic Myelomonocytic Leukaemia. A Report on Behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kr\u00f6ger","year":"2002","journal-title":"Br J Haematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Chronic Myelomonocytic Leukemia","volume":"37","author":"Elliott","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.366","article-title":"Outcome of Allo-SCT for Chronic Myelomonocytic Leukemia","volume":"43","author":"Ocheni","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.375","article-title":"Allogeneic Haematopoietic SCT for Chronic Myelomonocytic Leukaemia: A Single-Centre Experience","volume":"45","author":"Krishnamurthy","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: A Report From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13576","article-title":"Achievement of Complete Remission Predicts Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Chronic Myelomonocytic Leukaemia. A Study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: Recommendations From an International Expert Panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I Treat Chronic Myelomonocytic Leukemia","volume":"130","author":"Solary","year":"2017","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2015.11.004","article-title":"Hypomethylating Agents as Bridging Therapy Before Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Chronic Myelomonocytic Leukemia","volume":"22","author":"Robin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.05.026","article-title":"Comparison of Intensive Chemotherapy and Hypomethylating Agents Before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research","volume":"22","author":"Potter","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"B50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbmt.2015.08.031","article-title":"Treatment With Hypomethylating Agents Before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients With Chronic Myelomonocytic Leukemia","volume":"22","author":"Kongtim","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"B51","first-page":"1129\u201330","article-title":"Low-Dose Cytosine Arabinoside in Adult Chronic Myelomonocytic Leukemia","volume":"5","author":"Fenaux","year":"1987","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1857","article-title":"A Critical Appraisal of Low-Dose Cytosine Arabinoside in Patients With Acute Non-Lymphocytic Leukemia and Myelodysplastic Syndromes","volume":"4","author":"Cheson","year":"1986","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"468\u201371","DOI":"10.1111\/j.1365-2141.1989.tb07735.x","article-title":"Treatment of CMML With Low Dose Etoposide","volume":"72","author":"Oscier","year":"1989","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A Randomized Trial of Hydroxyurea Versus VP16 in Adult Chronic Myelomonocytic Leukemia. Groupe Francais Des Myelodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: Matched-Pair Analyses of Daily-Life Patients Reveal Modest Effects on Clinical Course and Survival","volume":"38","author":"Pleyer","year":"2014","journal-title":"Leuk Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138680","article-title":"The American Society of Hematology\u201562nd Annual Meeting and Exposition. Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the EMSCO Randomized Phase 3 DACOTA Trial","volume":"136","author":"Itzykson","year":"2020","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01330-1","article-title":"Increasing Recognition and Emerging Therapies Argue for Dedicated Clinical Trials in Chronic Myelomonocytic Leukemia","volume":"35","author":"Renneville","year":"2021","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients With Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS Mutations Drive Proliferative Chronic Myelomonocytic Leukemia via a KMT2A-PLK1 Axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01240-2","article-title":"Activity of Venetoclax-Based Therapy in Chronic Myelomonocytic Leukemia","volume":"35","author":"Montalban-Bravo","year":"2021","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.801524\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T05:25:54Z","timestamp":1639373154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.801524\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":60,"alternative-id":["10.3389\/fonc.2021.801524"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.801524","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"article-number":"801524"}}